Managing Chronic Asthma in Adults

When managing chronic asthma in adults, it is important to consider the patient’s current treatment plan and symptoms. In this scenario, the patient is already taking a combination inhaler and is experiencing suboptimal control of her asthma. It is important to note that this is not an acute attack and the children’s guidelines do not apply. Antibiotics are not recommended as the symptoms are not consistent with an infective exacerbation. Increasing the usage of salbutamol is also not recommended as the patient needs better overall control of her symptoms. Instead, the dose of the inhaled corticosteroid should be increased, which is in line with the next step in the treatment of asthma in adults according to the British Thoracic Society guidelines. It is important for healthcare professionals to be familiar with both SIGN and NICE guidance and be able to compare and contrast their advice.

As an ex-smoker, this woman is experiencing a gradual improvement in her consolidation, but she still has a persistent cough. It is recommended that she be referred for further evaluation under the 2 week wait rule to rule out the possibility of lung cancer.

Referral Guidelines for Lung Cancer

Lung cancer is a serious condition that requires prompt diagnosis and treatment. The 2015 NICE cancer referral guidelines provide clear advice on when to refer patients for suspected lung cancer. According to these guidelines, patients should be referred using a suspected cancer pathway referral for an appointment within 2 weeks if they have chest x-ray findings that suggest lung cancer or are aged 40 and over with unexplained haemoptysis.

For patients aged 40 and over who have 2 or more unexplained symptoms such as cough, fatigue, shortness of breath, chest pain, weight loss, or appetite loss, an urgent chest x-ray should be offered within 2 weeks to assess for lung cancer. This recommendation also applies to patients who have ever smoked and have 1 or more of these unexplained symptoms.

In addition, patients aged 40 and over with persistent or recurrent chest infection, finger clubbing, supraclavicular lymphadenopathy or persistent cervical lymphadenopathy, chest signs consistent with lung cancer, or thrombocytosis should be considered for an urgent chest x-ray within 2 weeks to assess for lung cancer.

Overall, these guidelines provide clear and specific recommendations for healthcare professionals to identify and refer patients with suspected lung cancer for prompt diagnosis and treatment.

Treatment Algorithm for COPD Patients

Page 9 of the NICE reference guide on Chronic obstructive pulmonary disease (CG101) provides an overview of the treatment algorithm for patients with COPD. If a patient has inadequately controlled symptoms despite using a regular short-acting beta agonist and an FEV1 of greater or equal to 50%, the next options are to add in a long-acting beta agonist or a long-acting muscarinic antagonist. In both cases, the short-acting beta agonist can continue to be used as required. Therefore, the correct answer from the list of options is to add in a regular long-acting muscarinic antagonist.

If the patient has an FEV1 <50%, the treatment choice would alter again with the option of using a long-acting beta agonist/inhaled corticosteroid combination inhaler. It is important to follow the treatment algorithm to ensure that patients receive the appropriate treatment for their COPD symptoms. Proper management of COPD can improve a patient's quality of life and reduce the risk of exacerbations.

NICE Guidelines for Referral of Suspected Lung Cancer Patients

The National Institute for Health and Care Excellence (NICE) has issued guidelines for the recognition and referral of suspected lung cancer patients. According to the guidelines, patients aged 40 and over with unexplained haemoptysis should be referred urgently for an appointment within two weeks, even if their chest x-ray is normal. Additionally, patients with two or more unexplained symptoms such as cough, fatigue, shortness of breath, chest pain, weight loss, or appetite loss, or those with persistent or recurrent chest infection, finger clubbing, supraclavicular lymphadenopathy or persistent cervical lymphadenopathy, chest signs consistent with lung cancer, or thrombocytosis should be offered an urgent chest x-ray within two weeks to assess for lung cancer. These guidelines aim to ensure timely diagnosis and treatment of lung cancer, which is crucial for improving patient outcomes.

BTS Guidance on Low Dose ICS and LABA Treatment

According to the 2016 BTS guidance, if a patient taking a low dose ICS doesn’t respond to the addition of a LABA, the LABA should be discontinued. Instead, healthcare providers should consider increasing the dose of ICS. It is important to note that options suggesting only an increase in ICS dose without stopping the LABA are incorrect.

This guidance emphasizes the importance of individualized treatment plans for patients with respiratory conditions. By carefully monitoring patient response to medication and adjusting treatment as needed, healthcare providers can help improve patient outcomes and quality of life. Proper medication management can also help reduce the risk of adverse effects and complications associated with respiratory conditions.

To alleviate his symptoms, the patient is taking his medication three times daily. Despite his condition, he remains alert and capable of speaking in complete sentences while at rest. His vital signs are as follows: temperature of 37.1ºC, pulse rate of 116/min, blood pressure of 118/70 mmHg, and respiratory rate of 2.

Management of Acute Asthma

Acute asthma is classified into moderate, severe, life-threatening, and near-fatal categories by the British Thoracic Society (BTS). Patients with life-threatening features should be treated as having a life-threatening attack. Further assessment may include arterial blood gases for patients with oxygen sats < 92%, and a chest x-ray is not routinely recommended unless there is life-threatening asthma, suspected pneumothorax, or failure to respond to treatment. Admission is necessary for all patients with life-threatening asthma, and patients with features of severe acute asthma should also be admitted if they fail to respond to initial treatment. Oxygen therapy is important for hypoxaemic patients, and bronchodilation with short-acting beta₂-agonists (SABA) is recommended. All patients should be given 40-50 mg of prednisolone orally (PO) daily, and nebulised ipratropium bromide may be used in severe or life-threatening cases. The evidence base for IV magnesium sulphate is mixed, and IV aminophylline may be considered following consultation with senior medical staff. Patients who fail to respond require senior critical care support and should be treated in an appropriate ITU/HDU setting. Criteria for discharge include being stable on their discharge medication, inhaler technique checked and recorded, and PEF >75% of best or predicted.

Effective Treatment for Acute Asthma

When it comes to treating acute asthma, steroid tablets and injected steroids are equally effective. A dose of oral prednisolone of 40-50 mg per day for at least five days or intravenous hydrocortisone 400 mg can be used. It is important to continue taking prednisolone until recovery, which should be a minimum of five days. Additionally, it is important to not stop inhaled corticosteroids during the prescription of oral corticosteroids. By following these key points, patients can effectively manage their acute asthma symptoms.

Treating Infective Exacerbation of Bronchiectasis

When managing a suspected infective exacerbation of bronchiectasis, it is crucial to obtain a sputum culture before initiating antibiotics. However, treatment should not be delayed until the culture results are available. It is also recommended to administer a more extended course of antibiotics than what is typically prescribed for a lower respiratory tract infection.

NICE provides specific guidance on the selection and duration of antibiotics based on the identified organism. Additionally, hospital admission should be considered if there are indications of a more severe illness, such as cyanosis, confusion, respiratory rate exceeding 25 breaths per minute, significant breathlessness, or a temperature of 38°C or higher.

Understanding Acute Opioid Toxicity

Acute opioid toxicity is a serious condition that can result in drowsiness, nausea, vomiting, and respiratory depression. The severity of symptoms may be exacerbated if alcohol or other sedatives are also involved. Hypotension is a common occurrence, and both tachycardia and bradycardia may be observed. Hypoventilation can lead to hypoxia-induced cardiac arrhythmias, and pinpoint pupils may be present. Sweating is more commonly associated with acute opioid withdrawal. It is important to seek medical attention immediately if you suspect acute opioid toxicity.

Methotrexate can lead to pulmonary fibrosis, while there is no evidence to suggest that terbinafine, paracetamol, montelukast, and tramadol have this side effect. The onset of pulmonary fibrosis due to low-dose methotrexate use can occur within weeks to months.

Methotrexate is an antimetabolite that hinders the activity of dihydrofolate reductase, an enzyme that is crucial for the synthesis of purines and pyrimidines. It is a significant drug that can effectively control diseases, but its side-effects can be life-threatening. Therefore, careful prescribing and close monitoring are essential. Methotrexate is commonly used to treat inflammatory arthritis, especially rheumatoid arthritis, psoriasis, and acute lymphoblastic leukaemia. However, it can cause adverse effects such as mucositis, myelosuppression, pneumonitis, pulmonary fibrosis, and liver fibrosis.

Women should avoid pregnancy for at least six months after stopping methotrexate treatment, and men using methotrexate should use effective contraception for at least six months after treatment. Prescribing methotrexate requires familiarity with guidelines relating to its use. It is taken weekly, and FBC, U&E, and LFTs need to be regularly monitored. Folic acid 5mg once weekly should be co-prescribed, taken more than 24 hours after methotrexate dose. The starting dose of methotrexate is 7.5 mg weekly, and only one strength of methotrexate tablet should be prescribed.

It is important to avoid prescribing trimethoprim or co-trimoxazole concurrently as it increases the risk of marrow aplasia. High-dose aspirin also increases the risk of methotrexate toxicity due to reduced excretion. In case of methotrexate toxicity, the treatment of choice is folinic acid. Overall, methotrexate is a potent drug that requires careful prescribing and monitoring to ensure its effectiveness and safety.